 |
Management Team | Board of Directors | Scientific Advisory Board | R&D Team
Gilbert Di Paolo, Ph.D.
Gilbert is an Assistant Professor in the Department of Pathology at the Columbia University Medical Center in New York. He received his Ph.D. from the University of Lausanne in Switzerland, although he conducted most of his graduate studies in the Department of Neurodegeneration of the Glaxo Institute for Molecular Biology in Geneva, Switzerland, under the supervision of Dr. Gabriele Grenningloh. The main goal of his graduate studies was to understand the molecular mechanisms underlying neuronal differentiation and survival promoted by neurotrophic factors. After completing his Ph.D., he moved to Yale University, where he conducted more than six years of postdoctoral research in the laboratory of Dr. Pietro De Camilli, a world expert in the field of neuronal membrane traffic. His main focus was to characterize the role of phosphoinositides in synaptic vesicle trafficking, largely using a mouse genetics approach. He acquired tremendous expertise in the field of lipid research and has made seminal contributions to understanding how phosphoinositide-metabolizing enzymes regulate processes as diverse as neurotransmission, secretion, and cell adhesion. At Columbia he continues to study the role of phosphoinositides in regulating membrane traffic with a strong emphasis on pathological processes, such as those associated with Down syndrome, Alzheimer's disease, and lipid storage disorders. Dr. Di Paolo has over 25 peer-reviewed publications in top scientific journals, and is a frequent invited speaker at symposia and conferences.
» Top of page
Ottavio Arancio, M.D., Ph.D.
Ottavio is a cellular neurobiologist who has contributed to the characterization of the mechanisms of learning in both normal conditions and during neurodegenerative diseases. During the past 5 years he has pioneered the field of mechanisms of synaptic dysfunction in Alzheimer's disease focusing primarily on events triggered by beta-amyloid. These studies, which have suggested new links between synaptic dysfunction and beta-amyloid, are relevant to the understanding of Alzheimer's disease. Ottavio received his M.D./Ph.D. from the University of Pisa (Italy). From 1981 to 1986 he underwent residency training in Neurology at the University of Verona (Italy) working on nerve muscle interaction. He spent 1987 to 1990 as a "Moruzzi" fellow at the Department of Physiology and Molecular Biophysics at Columbia University working with Dr. A. MacDermott on the distribution of excitatory amino-acid receptors in spinal-cord neurons. In 1991 he was recruited to the laboratory of Cellular and Molecular Neurobiology (Pasteur Institute, Paris, France) to work on the biology of the hippocampus. In 1992 he returned to Columbia University to work at the Center for Neurobiology and Behavior with Dr. Eric Kandel and R. Hawkins on normal mechanisms of learning. Ottavio has held Faculty appointments at Columbia University, NYU School of Medicine and at State University of New York (SUNY) -- Health Science Center at Brooklyn. In 2004 he became Faculty member of the Department of Pathology and The Taub Institute for Research on Alzheimer's Disease and the Aging Brain at Columbia University. His honors include the G. Moruzzi Fellowship at (Georgetown), the Anna Villa Rusconi Foundation Prize (Italy), and the INSERM Poste Vert Fellowship (France).
» Top of page
Donald W. Landry, M.D., Ph.D.
Donald is a Professor of Medicine and the Director of the Division of Clinical Pharmacology and Experimental Therapeutics and the Division of Nephrology in the Department of Medicine at Columbia University. He completed his Ph.D. in organic chemistry under the guidance of the Nobel laureate Robert Burns Woodward at Harvard University in 1979 and obtained an M.D. degree from Columbia University in 1983. After completing his residency in Internal Medicine at the Massachusetts General Hospital, he returned to Columbia University as an NIH Physician-Scientist from 1985 to 1990. During this period, he also completed subspecialty training in nephrology. In 1991, he established a laboratory at Columbia University to investigate medical applications of artificial enzymes. His laboratory focuses on organic chemical solutions to intractable medical problems such as cocaine addiction and nerve gas intoxication. His work has also led to the discovery of a pathogenetic deficiency of the hormone vasopressin in vasodilatory shock. He most recently founded the Organic Synthesis Collaborative Center at Columbia through funding from Merck, Inc. to provide small molecules for preclinical validation of targets for pharmaceutical development.
» Top of page
Korea Research Institute for Chemical Technology/Center for Biological Modulators
» Top of page
| |
